|

PD-1/PD-L1 monoclonal antibodies Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Chuangzhen Chen1

Indications

  • Drug Resistance1
  • Esophageal Neoplasms Malignant1
  • Immune Checkpoint Blockade1
  • Lung Neoplasm Malignant1
  • Metastatic Solid Cancers1

Other1 trial

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.